These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35032356)

  • 1. Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1.
    Kristensen LE; Soliman AM; Papp K; Merola JF; Barcomb L; Wang Z; Eldred A; Behrens F
    J Eur Acad Dermatol Venereol; 2022 May; 36(5):e389-e392. PubMed ID: 35032356
    [No Abstract]   [Full Text] [Related]  

  • 2. Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis.
    Reich K; Baraliakos X; Coates LC; Elewski B; Bao W; Kasparek T; Gaillez C; Pournara E; Aassi M; Perella C; Gottlieb AB
    Br J Dermatol; 2022 Sep; 187(3):438-441. PubMed ID: 35257363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative microscopic analysis of nail clippings from patients with cutaneous psoriasis and psoriatic arthritis.
    Fonseca GP; Werner B; Seidel G; Staub HL
    An Bras Dermatol; 2017; 92(1):21-25. PubMed ID: 28225951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel combination biologic therapy for recalcitrant psoriasis and psoriatic arthritis in a medically complex patient.
    Hanna S; Youssef P; Lowe P
    Australas J Dermatol; 2022 Feb; 63(1):e63-e66. PubMed ID: 34813085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials.
    Merola JF; Armstrong A; Khattri S; Paek SY; Padilla B; Yue C; Photowala H; Kaplan B; Kristensen LE
    J Dermatolog Treat; 2024 Dec; 35(1):2342383. PubMed ID: 38632977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical improvement in psoriatic nail disease and psoriatic arthritis with tildrakizumab treatment.
    Ismail FF; May J; Moi J; Sinclair R
    Dermatol Ther; 2020 Mar; 33(2):e13216. PubMed ID: 31899569
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.
    Kristensen LE; Keiserman M; Papp K; McCasland L; White D; Lu W; Wang Z; Soliman AM; Eldred A; Barcomb L; Behrens F
    Ann Rheum Dis; 2022 Feb; 81(2):225-231. PubMed ID: 34911706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis.
    Wells LE; Evans T; Hilton R; Wine Lee L; Ruth N
    Pediatr Dermatol; 2019 May; 36(3):384-385. PubMed ID: 30811618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The untold burden of isolated nail psoriasis: Delayed diagnosis and significant risk of psoriatic arthritis in a retrospective study at an academic center.
    Chang MJ; Lee D; Desai AD; Lipner SR
    J Am Acad Dermatol; 2023 May; 88(5):1192-1194. PubMed ID: 36621466
    [No Abstract]   [Full Text] [Related]  

  • 10. New insight into the pathogenesis of nail psoriasis and overview of treatment strategies.
    Ventura A; Mazzeo M; Gaziano R; Galluzzo M; Bianchi L; Campione E
    Drug Des Devel Ther; 2017; 11():2527-2535. PubMed ID: 28919705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The nail dystrophy of psoriatic arthritis.
    Eastmond CJ; Wright V
    Ann Rheum Dis; 1979 Jun; 38(3):226-8. PubMed ID: 485578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab therapy of psoriasis and psoriatic arthritis in a patient with cirrhosis of the liver.
    Piel S; Dissemond J
    J Am Acad Dermatol; 2008 Nov; 59(5 Suppl):S117-8. PubMed ID: 19119119
    [No Abstract]   [Full Text] [Related]  

  • 13. Psoriatic arthritis improved on risankizumab: does the presence of psoriatic arthritis mean a drug approved for psoriatic arthritis has to be prescribed?
    Singh R; Brown AM; Chan WH; Farr MA; Venkataraman S; Feldman SR
    Expert Opin Biol Ther; 2022 Dec; 22(12):1439-1441. PubMed ID: 35678210
    [No Abstract]   [Full Text] [Related]  

  • 14. Risankizumab: First Global Approval.
    McKeage K; Duggan S
    Drugs; 2019 Jun; 79(8):893-900. PubMed ID: 31098898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab in psoriasis and psoriatic arthritis.
    Papoutsaki M; Osório F; Morais P; Torres T; Magina S; Chimenti S; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():13-23. PubMed ID: 23990278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended report: nail disease in psoriatic arthritis--clinically important, potentially treatable and often overlooked.
    Williamson L; Dalbeth N; Dockerty JL; Gee BC; Weatherall R; Wordsworth BP
    Rheumatology (Oxford); 2004 Jun; 43(6):790-4. PubMed ID: 15113998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study.
    Paul C; van de Kerkhof P; Puig L; Unnebrink K; Goldblum O; Thaçi D
    Eur J Dermatol; 2012; 22(6):762-9. PubMed ID: 23178916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ustekinumab for psoriatic arthritis.
    Cuchacovich RS; Espinoza LR
    Lancet; 2009 Feb; 373(9664):605-6. PubMed ID: 19217153
    [No Abstract]   [Full Text] [Related]  

  • 19. Nail pitting: a key clinical sign of psoriatic arthritis.
    Jha S; Kumar RR; Dhooria A; Sharma A
    Rheumatology (Oxford); 2019 Dec; 58(12):2250. PubMed ID: 31329990
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapies for psoriatic nail disease. A systematic review.
    Cassell S; Kavanaugh AF
    J Rheumatol; 2006 Jul; 33(7):1452-6. PubMed ID: 16724366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.